In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?

Abstract

In intermediate HCC stage patients, both treatments resulted in similar survival probabilities despite more advanced disease in the TARE Y-90 group. Still, TARE Y-90 was better tolerated and associated with less hospitalization and treatment sessions.

Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis

“…The meta-analysis showed that the OS was significantly better in the TARE with Y90 group than in the TACE group. The pooled HR for the (346 patients) (25,(27)(28)(29). The meta-analysis showed that the hospitalization time days was significantly shorter in the TARE with Y90 group than in the TACE group.…”

“…Three studies reported the BCLC stage, and more than half of the patients were in BCLC-B stage (24)(25)(26). The median pretreatment MELD score ranged from 7.5 to 10 (23,25,28,29). All the included patients were definitely diagnosed to conform to the eligibility criteria.…”

“…The baseline liver function of most included patients was in Child-Pugh A (23)(24)(25)(26)(27)(28)(29). The etiology of the included patients were reported in seven studies, and most of the patients were a result from HCV and alcohol (23)(24)(25)(26)(28)(29)(30). Three studies reported the BCLC stage, and more than half of the patients were in BCLC-B stage (24)(25)(26).…”

“…Four of the eight studies included in the meta-analysis reported the results of data on hospitalization time days were conducted in USA (24)(25)(26)(27)(28)30), one in China (23), one in Germany combined with Egypt (29). All the studies were published in English.…”

“…After 1,494 studies were excluded, the remaining 49 studies were examined at length. Finally, seven case control studies (23)(24)(25)(26)(27)(28)(29) and one cohort study (30) were eligible for inclusion criteria ( Figure 1). A total of 1,499 patients were included among the eight studies, with 451 patients in the TARE group and 1,048 patients in TACE group.…”